Vyant Bio, Inc. – NASDAQ:VYNT

Add to watchlist

$0.215

+0.02

+10.82%

Market closed

Open in 2 days

+9.30%

month

+14.12%

quarter

-76.06%

year

Market Cap	N/A
Enterprise value	N/A

P/E	-0.2
EV/Sales	-4.33
EV/EBITDA	0.16
Price/Sales	2.58
Price/Book	0.29
PEG ratio	N/A
EPS	-4.9

Revenue	666K
EBITDA	-15.06M
Income	-28.70M
Revenue Q/Q	N/A
Revenue Y/Y	-41.98%

Profit margin	-3320.81%
Oper. margin	-2173.28%
Gross margin	35.27%
EBIT margin	-2173.28%
EBITDA margin	-2262.61%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Vyant Bio, Inc. (NASDAQ:VYNT): Profit margin
Mar 2022	303K	-9.17M	-3027.06%
Jun 2022	165K	-5.79M	-3511.52%
Sep 2022	152K	-3.42M	-2255.92%
Dec 2022	46K	-10.31M	-22417.39%

Vyant Bio, Inc. (NASDAQ:VYNT): Debt to assets
Mar 2022	32529000	10.16M	31.24%
Jun 2022	26811000	10.02M	37.39%
Sep 2022	23039000	9.19M	39.93%
Dec 2022	15205000	5.29M	34.83%

Vyant Bio, Inc. (NASDAQ:VYNT): Cash Flow
Mar 2022	-3.97M	-60K	-136K
Jun 2022	-4.16M	-373K	-202K
Sep 2022	-2.25M	-251K	197K
Dec 2022	-3.29M	3.94M	-8K

Vyant Bio alternative data

Vyant Bio, Inc. (NASDAQ:VYNT): Employee count
Aug 2023	8
Sep 2023	4
Oct 2023	4
Nov 2023	4
Dec 2023	4
Jan 2024	4
Feb 2024	4
Mar 2024	4
Apr 2024	4
May 2024	4
Jun 2024	4
Jul 2024	4

Vyant Bio
Hedge Funds Holdings Q1 2023

1.59% -33.58%

of VYNT is owned by hedge funds

9 -5

hedge funds hold VYNT stock

93.59K -224.58K

shares is hold by hedge funds

VYNT hedge funds holdings changes

Vyant Bio, Inc. (NASDAQ:VYNT): Insider trades (number of shares)
Period	Buy	Sel
Dec 2021	5000	0
Nov 2022	0	765

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Sale	18 Nov 2022	HARRIS GEOFFREY E. director director	Common Stock, $0.0001 par value	666	$1.33	$888
Sale	18 Nov 2022	HARRIS GEOFFREY E. director director	Common Stock, $0.0001 par value	99	$1.34	$133
Purchase	6 Dec 2021	BOEHM MARCUS director director	Common Stock, $0.0001 par value	5,000	$1.69	$8,450
Purchase	24 Nov 2021	ROBERTS JOHN A officer: Chief Executive Officer officer: Chief Executive Officer	Common Stock, $0.0001 par value	5,000	$2.02	$10,100
Purchase	23 Nov 2021	LAFRENCE ANDREW D.C. officer: Chief Financial Officer officer: Chief Financial Officer	Common Stock, $0.0001 par value	5,000	$2	$10,000
Purchase	22 Nov 2021	YEH YUNG-PING director, officer: Chief Innovation Officer director, officer: Chief Innova..	Common Stock, $0.0001 par value	500	$2.05	$1,025
Purchase	28 Oct 2021	FREMEAU ROBERT THOMAS JR. officer: Chief Scientific Officer officer: Chief Scientific Officer	Common Stock, $0.0001 par value	1,000	$2.19	$2,190
Purchase	27 Oct 2021	BOEHM MARCUS director director	Common Stock, $0.0001 par value	5,000	$2.1	$10,500
Purchase	29 Sep 2021	BOEHM MARCUS director director	Common Stock, $0.0001 par value	5,000	$2.44	$12,200
Purchase	25 Aug 2021	BOEHM MARCUS	Common Stock, $0.0001 par value	5,000	N/A	N/A

Vyant Bio
Earnings Call Transcripts

Quarter	Transcript
Q3 2022 17 Nov 2022	Q3 2022 Earnings Call Transcript
Q2 2022 22 Aug 2022	Q2 2022 Earnings Call Transcript
Q1 2022 16 May 2022	Q1 2022 Earnings Call Transcript
Q4 2021 30 Mar 2022	Q4 2021 Earnings Call Transcript

VYNT earnings call transcripts

Vyant Bio
Executives

Insider	Age	Since	Compensation
Dr. Robert J. Petcavich (1954) Chief Science Advisor & Director	71		$212,480
Mr. Andrew D.C. LaFrence CPA, CPA (1963) Chief Financial Officer & Chief Operating Officer	62		$106,070

Vyant Bio
Latest News

Tuesday, 26 December 2023
09:15	Vyant Bio Provides Update on Winddown Activities	globenewswire.com
Friday, 10 November 2023
16:05	Vyant Bio Provides Update on Winddown Activities	globenewswire.com
Friday, 12 May 2023
09:21	Vyant Bio to pursue listing on OTC Pink Open Market	Proactive Investors
Tuesday, 25 April 2023
08:53	Why Is Vyant Bio (VYNT) Stock Down 35% Today?	InvestorPlace
Friday, 3 February 2023
07:02	Vyant Bio commences cash conservation plan including ‘reduction in force' as it continues to explore strategic alternatives	Proactive Investors
Wednesday, 4 January 2023
16:43	Vyant Bio appoints LifeSci Capital to review strategy focused on enhancing shareholder value	Proactive Investors
Thursday, 17 November 2022
17:26	Vyant Bio, Inc. (VYNT) Q3 2022 Earnings Call Transcript	Seeking Alpha
Tuesday, 15 November 2022
11:07	Vyant Bio in position to be fully funded through 2023 following sale of subsidiary, 3Q results show	Proactive Investors
Friday, 11 November 2022
09:34	Vyant Bio showcases 'promise and potential' of its drug discovery platform at Boston medical conference	Proactive Investors
Thursday, 3 November 2022
11:06	Vyant Bio sells biotech branch vivoPharm to Reaction Biology for $5.5 million	Proactive Investors
Monday, 24 October 2022
16:15	Vyant Bio to Present at the LD Micro Main Event XV on Wednesday, October 26, 2022	GlobeNewsWire
Wednesday, 31 August 2022
08:00	Vyant Bio to Present at the H.C. Wainwright 24th Annual Global Investment Conference	GlobeNewsWire
Tuesday, 23 August 2022
07:07	Vyant Bio posts Q2 results, set to advance VYNT-0126 to treat Rett Syndrome into clinical trials early next year	Proactive Investors
Monday, 22 August 2022
23:00	Vyant Bio, Inc. (VYNT) CEO Jay Roberts on Q2 2022 Results - Earnings Call Transcript	Seeking Alpha
Friday, 19 August 2022
09:29	Vyant Bio Announces Rescheduled Investor Conference Call and Webcast for the Second Quarter and First Half of 2022	GlobeNewsWire
Monday, 15 August 2022
08:05	Vyant Bio Postpones Second Quarter Investor Conference Call and Webcast	GlobeNewsWire
Thursday, 11 August 2022
08:00	Vyant Bio Announces Investor Conference Call and Webcast for the Second Quarter and First Half of 2022	GlobeNewsWire
Monday, 16 May 2022
20:39	Vyant Bio, Inc. (VYNT) CEO Jay Roberts on Q1 2022 Results - Earnings Call Transcript	Seeking Alpha
10:40	Vyant Bio ends 1Q with $16.4M in cash to fund small molecule therapeutics research for neurological diseases	Proactive Investors
Tuesday, 10 May 2022
16:01	Vyant Bio Announces Investor Conference Call and Webcast for the First Quarter 2022	GlobeNewsWire
Wednesday, 30 March 2022
13:41	Top Penny Stocks Today: Why Are ADGI, DRCT, VYNT, NAOV, GERN and SNOA Rising Today?	InvestorPlace
12:41	Vyant Bio, Inc. (VYNT) CEO Jay Roberts on Q4 2021 Results - Earnings Call Transcript	Seeking Alpha
12:06	Vyant Bio ends 2021 with $20.6M in cash as it sharpens focus on novel drug discovery	Proactive Investors
09:30	Trading Penny Stocks? Top Stock Market News for March 30th, 2022	PennyStocks
07:20	Vyant Bio enters collaboration with OrganoTherapeutics to find treatments for Parkinson's Disease	Proactive Investors
06:25	Vyant Bio Shares Jump On Parkinson's Disease Agreement	Benzinga
Monday, 28 March 2022
16:30	Vyant Bio Announces Investor Conference Call and Webcast for the Year-End 2021	GlobeNewsWire
Tuesday, 1 March 2022
12:20	Vyant Bio says it is ‘well-positioned' to discover novel therapeutics to treat neurological diseases	Proactive Investors
Monday, 29 November 2021
09:15	Vyant Bio to Present at The Benchmark Company Discovery One-on-One Investor Conference	GlobeNewsWire
Monday, 15 November 2021
14:50	Vyant Bio's (VYNT) CEO Jay Roberts on Q3 2021 Results - Earnings Call Transcript	Seeking Alpha

Frequently Asked Questions (FAQ)

What's the price of Vyant Bio stock today?

One share of Vyant Bio stock can currently be purchased for approximately $0.22.
When is Vyant Bio's next earnings date?

Unfortunately, Vyant Bio's (VYNT) next earnings date is currently unknown.
Does Vyant Bio pay dividends?

No, Vyant Bio does not pay dividends.
What is Vyant Bio's stock symbol?

Vyant Bio, Inc. is traded on the NASDAQ under the ticker symbol "VYNT".
What is Vyant Bio's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Vyant Bio?

Shares of Vyant Bio can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Vyant Bio's key executives?
Vyant Bio's management team includes the following people:
- Dr. Robert J. Petcavich Chief Science Advisor & Director(age: 71, pay: $212,480)
- Mr. Andrew D.C. LaFrence CPA, CPA Chief Financial Officer & Chief Operating Officer(age: 62, pay: $106,070)
How many employees does Vyant Bio have?

As Jul 2024, Vyant Bio employs 4 workers.
When Vyant Bio went public?

Vyant Bio, Inc. is publicly traded company for more then 4 years since IPO on 1 Apr 2021.
What is Vyant Bio's official website?

The official website for Vyant Bio is vyantbio.com.
Where are Vyant Bio's headquarters?

Vyant Bio is headquartered at 2 Executive Campus, Cherry Hill, NJ.
How can i contact Vyant Bio?

Vyant Bio's mailing address is 2 Executive Campus, Cherry Hill, NJ and company can be reached via phone at +20 14791357.

Vyant Bio, Inc.

vyantbio.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

Vyant Bio, Inc., a biotechnology company, discovers drugs for complex neurodevelopmental and neurodegenerative disorders. The company's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. It focuses on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome (Rett), CDKL5 deficiency disorders (CDD,) and familial Parkinson's disease (PD). Vyant Bio, Inc. has a collaboration agreement to discover drugs for the treatment of Parkinson's Disease. The company is based in Cherry Hill, New Jersey.

+20 14791357

2 Executive Campus
Cherry Hill, NJ 08002

CIK: 0001349929
ISIN: US92942V2088
CUSIP: 92942V109